Rankings
▼
Calendar
ORGO Q4 2024 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena
ORGO
Organogenesis Holdings Inc.
$355M
Q4 2024 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$127M
+27.1% YoY
Gross Profit
$96M
75.5% margin
Operating Income
$10M
8.1% margin
Net Income
$8M
6.1% margin
EPS (Diluted)
$0.04
QoQ Revenue Growth
+10.0%
Cash Flow
Operating Cash Flow
$11M
Free Cash Flow
$8M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$498M
Total Liabilities
$113M
Stockholders' Equity
$385M
Cash & Equivalents
$136M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$127M
$100M
+27.1%
Gross Profit
$96M
$72M
+33.0%
Operating Income
$10M
-$1M
+905.3%
Net Income
$8M
-$568,000
+1450.9%
Revenue Segments
Advanced Wound care
$242M
94%
Surgical and Sports Medicine
$15M
6%
← FY 2024
All Quarters
Q1 2025 →